Skip to content
Rolimus

CIPLA LTD.

Rolimus


“Rolimus” contains Drug / Molecule called “Everolimus”.

Everolimus, an immunosuppressive drug, is prescribed for the management of graft rejection in graft versus host disease (GVHD) in organ transplanted patients. It belongs to a class of medications called as protein kinase inhibitor. Rolimus is a potent inhibitor of the growth and proliferation of tumour cells, has shown to reduce glycolysis.


Indication

Rolimus is commonly prescribed in kidney and / or liver transplanted, renal cancer patients.

Medical Uses:

Everolimus is approved for various conditions:

  • Advanced kidney cancer (US FDA approved in March 2009)
  • Prevention of organ rejection after renal transplant (US FDA April 2010)
  • Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (US FDA October 2010)
  • Progressive or metastatic pancreatic neuroendocrine Tumors not surgically removable (May 2011)
  • Breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer, in conjunction with Exemestane (US FDA July 2012)
  • Prevention of organ rejection after liver transplant(Feb 2013)
  • Progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease (US FDA February 2016).
  • Tuberous sclerosis complex-associated partial-onset seizures for adult and Pediatric patients aged 2 years and older. (US FDA April 2018).

Note

SIDE EFFECTS :

Non-Infectious Pneumonitis, Infections, Severe Hypersensitivity reactions, Angioedema, Renal Failure.

INTERACTION :

  • Avoid the concomitant use of P-gp and strong CYP3A4 inhibitors.
  • Patients taking concomitant ACE inhibitors with Rolimus may be at increased risk for angioedema. Avoid the concomitant use of ACE inhibitors with Rolimus

OVERDOSE :

  • Do not use more than prescribed dose.
  • If you suspect you may have overdosed, call your healthcare provider.
  • Do not take extra dose to make up for the missed dose.

Precaution

  • Rolimus is a prescription drug and should be used under proper medical guidance and advice.
  • Contraindicated in patients with clinical history of melanoma, clotting disorders, hepatic diseases.

Updated On Oct 21, 2019 by Admin

Strength

5mg, 10mg

Packing

1 X 10 Tablets (Strip)

Storage

Store at a room temperature not exceeding 30 C



Related Products


CIPLA LTD.

Rolimus

CIPLA LTD.

Valcip

CIPLA LTD. (INDIA)

Bosentan-bosentas

CIPLA LTD.

Bosentas


Most Viewed Products


CIPLA LTD. (INDIA)

Abiraterone acetate-xbira

NATCO PHARMA LIMITED (INDIA)

Bendamustine-bendit

CIPLA LTD. (INDIA)

Bicalutamide-cassotide

NATCO PHARMA LIMITED (INDIA)

Bortezomib-bortenat

NATCO PHARMA LIMITED (INDIA)

Erlonat

Biocon Limited

Everolimus-evertor

NATCO PHARMA LIMITED (INDIA)

Exemestane-xtane

NATCO PHARMA LIMITED (INDIA)

Geftinat

NATCO PHARMA LIMITED (INDIA)

Glatiramer acetate-glatimer

NATCO PHARMA LIMITED (INDIA)

Ledipasvir & sofosbuvir-hepcinat lp

NATCO PHARMA LIMITED (INDIA)

Lenalidomide-lenalid

NATCO PHARMA LIMITED (INDIA)

Pomalidomide-pomalid

NATCO PHARMA LIMITED (INDIA)

Sofosbuvir & velpatasvir-velpanat

NATCO PHARMA LIMITED (INDIA)

Sorafenib-sorafenat

CIPLA LTD. (INDIA)

Tenofovir-tenvir

Top Products

Lenvatinib  | Sunishil

Sunitinib-Sutinat

Sunitinib-Sutinat

Quick Query

Direct to your Phone